Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Status:
Completed
Trial end date:
2020-06-17
Target enrollment:
Participant gender:
Summary
This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing
the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12
years of age or older. Approximately 415 subjects will be enrolled in this study at about 100
sites in North America, and Europe. The planned duration of treatment with study drug is 28
weeks.
Study drug will be lenabasum 20 mg BID, lenabasum 5 mg BID, and placebo in a 2:1:2 ratio.
Phase:
Phase 2
Details
Lead Sponsor:
Corbus Pharmaceuticals Inc.
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics